Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Gilead Sciences has announced that the FDA has granted marketing approval for Viread for the treatment of chronic hepatitis B, a liver disease caused by the hepatitis B virus.
Subscribe to our email newsletter
Viread is now also indicated for the treatment of chronic hepatitis B in adults. The drug is administered as a once-daily tablet, and works by blocking hepatitis B virus DNA polymerase, the enzyme that is necessary for the virus to replicate in liver cells. Viread has been available in the US as a treatment for HIV infection in adults since 2001.
Kevin Young, executive vice president of commercial operations at Gilead Sciences, said: “The approval of Viread for hepatitis B represents more than a decade of work in both the fields of HIV and hepatitis B to develop a medication that offers significant viral suppression, once-daily dosing and a well-established safety profile.”